Schizophrenia treatment preferences of psychiatrists versus guidelines: A European perspective
Open Access
- 1 August 2025
- journal article
- review article
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-50
Abstract
Background: We aimed to identify therapeutic approaches for managing schizophrenia in different phases and clinical situations – the prodromal phase, first-episode psychosis, cognitive and negative symptoms, pregnancy, treatment resistance, and antipsychotic-induced metabolic side effects – while assessing clinicians’ adherence to guidelines. Methods: A cross-sectional online survey was conducted in 2023 as part of the Ambassador project among psychiatrists and trainees from 35 European countries, based on a questionnaire that included six clinical vignettes (cases A–F). Additionally, a review of multiple guidelines/guidance papers was performed. Results: The final analysis included 454 participants. Our findings revealed a moderate to high level of agreement among European psychiatrists regarding pharmacological treatment preferences for first-episode psychosis and cognitive and negative symptoms, prodromal symptoms and pregnancy, with moderate adherence to clinical guidelines. There was substantial similarity in treatment preferences for antipsychotic-induced metabolic side effects and treatment resistance; however, adherence to guidelines in these areas was only partial. Despite guideline recommendations, non-pharmacological treatments, including psychotherapy and recovery-oriented care, were generally underutilized, except for psychoeducation and lifestyle recommendations, and cognitive behavioural therapy for treatment of the prodromal phase. Contrary to guidelines, cognitive remediation and physical exercise for cognitive symptoms were significantly neglected. Conclusions: These discrepancies highlight the need for effective implementation strategies to bridge the gap between research evidence, clinical guidelines/guidance papers, and real-world clinical practice. Clinicians’ unique combination of knowledge and experience positions them to shape future guidelines, especially where real-world practice diverges from recommendations, reinforcing the need to integrate both research evidence and clinical consensus.Keywords
This publication has 75 references indexed in Scilit:
- Antipsychotic long-acting injections: Prescribing practice in the UKThe British Journal of Psychiatry, 2009
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisThe Lancet, 2009
- Subjective Symptoms of Schizophrenia in Research and the Clinic: The Basic Symptom ConceptSchizophrenia Bulletin, 2009
- Gene-Environment Interactions in Schizophrenia: Review of Epidemiological Findings and Future DirectionsSchizophrenia Bulletin, 2008
- Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy VolunteersAmerican Journal of Psychiatry, 2006
- Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental StatesAustralian & New Zealand Journal of Psychiatry, 2005
- Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical featuresSchizophrenia Research, 2004
- From best evidence to best practice: effective implementation of change in patients' careThe Lancet, 2003
- Usefulness and limitations of treatment guidelines in psychiatry.2002